Anguilla vs Bonaire, Sint Eustatius and Saba: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Anguilla
0.2%
in 2024
Bonaire, Sint Eustatius and Saba
0.2%
in 2024
Anguilla rank
98th
Bonaire, Sint Eustatius and Saba rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Anguilla
- Bonaire, Sint Eustatius and Saba
How they compare
Anguilla currently reports 0.2% against 0.2% in Bonaire, Sint Eustatius and Saba, a difference of 0.0%.
Across all 10 years both countries report, Bonaire, Sint Eustatius and Saba has been ahead every year.
Anguilla ranks 98th and Bonaire, Sint Eustatius and Saba ranks 98th of 246 countries.
Head to head by decade
| Decade | Anguilla | Bonaire, Sint Eustatius and Saba | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Anguilla or Bonaire, Sint Eustatius and Saba?
- Anguilla, at 0.2% against 0.2% in Bonaire, Sint Eustatius and Saba as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Anguilla and Bonaire, Sint Eustatius and Saba?
- 0.0%, with Anguilla ahead.
- How many years of comparable data are there for Anguilla and Bonaire, Sint Eustatius and Saba?
- 10 years are reported by both, from 2015 to 2024.
- How do Anguilla and Bonaire, Sint Eustatius and Saba rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Anguilla ranks 98th and Bonaire, Sint Eustatius and Saba ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.